Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

45
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
45
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

162
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
162
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

83
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
83
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

131
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
131

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.

Swiss medical weekly·2025
Same author

Unanticipated Global Emergence of Multiple <i>Pneumocystis jirovecii</i> Mutants Selected by Mycophenolic Acid Driving Increasing Outbreaks in Solid Organ Transplant Recipients.

medRxiv : the preprint server for health sciences·2025
Same author

[Paraneoplastic limbic encephalitis - an important differential diagnosis in cases of unclear encephalopathy].

Praxis·2025
Same author

Perinephric myxoid pseudotumor of fat - histopathological and molecular characterization of 3 cases after renal transplantation.

Diagnostic pathology·2025
Same author

[Albumin-corrected calcium].

Praxis·2025
Same author

JC Polyomavirus Nephropathy: A Rare Complication Late after Kidney Transplantation.

Case reports in nephrology and dialysis·2024
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Related Experiment Video

Updated: Nov 8, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

[CME: Giant Cell Arteritis].

Katrin Reiner1, Thomas Fehr1, Jürg Wick1,2

  • 1Innere Medizin, Kantonsspital Graubünden, Chur.

Praxis
|April 28, 2021
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis (GCA) is a common vasculitis in those over 50, potentially causing vision loss. Tocilizumab offers a safer, more effective treatment alternative to long-term steroid use.

Keywords:
GCAGiant cell arteritisRZARiesenzellarteriitisTocilizumabVaskulitistocilizumabvasculitis

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

879
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.2K

Related Experiment Videos

Last Updated: Nov 8, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

879
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.2K

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is the most prevalent vasculitis affecting individuals over 50 years old.
  • It primarily targets large blood vessels, leading to cranial and extra-cranial manifestations.
  • Symptoms vary widely, from headaches and visual disturbances to systemic complaints like fatigue and fever.

Purpose of the Study:

  • To review the current understanding of Giant Cell Arteritis.
  • To discuss diagnostic challenges and the critical need for timely intervention.
  • To evaluate treatment options, focusing on steroids and newer alternatives.

Main Methods:

  • Literature review of Giant Cell Arteritis (GCA) diagnosis and treatment.
  • Analysis of current treatment recommendations and guidelines.
  • Comparison of efficacy and safety profiles of different therapeutic agents.

Main Results:

  • GCA presents with diverse symptoms, necessitating prompt diagnosis to prevent irreversible complications like vision loss.
  • Corticosteroids have been the mainstay of treatment for decades but are associated with significant side effects.
  • Tocilizumab has emerged as a more effective and safer therapeutic option.

Conclusions:

  • Early diagnosis and treatment of GCA are crucial to avert severe outcomes.
  • While steroids remain a standard treatment, their adverse effects are a concern.
  • Tocilizumab presents a promising alternative for managing Giant Cell Arteritis, offering improved safety and efficacy.